Porous drug matrices and methods of manufacture thereof

Details Porous drug matrices and methods of manufacture thereof Porous drug matrices and methods of manufacture thereof

2011-04-05

2011-04-05

Fubara, Blessing M (Department: 1613)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

C424S484000, C424S501000, C264S005000

Reexamination Certificate

active

07919119

ABSTRACT:
Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystallization. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.

REFERENCES:
patent: 4818542 (1989-04-01), DeLuca et al.
patent: 5064640 (1991-11-01), Kleber et al.
patent: 5271961 (1993-12-01), Mathiowitz et al.
patent: 5382437 (1995-01-01), Ecanow
patent: 5413797 (1995-05-01), Khan et al.
patent: 5468598 (1995-11-01), Miller et al.
patent: 5470583 (1995-11-01), Na et al.
patent: 5500331 (1996-03-01), Czekai et al.
patent: 5510118 (1996-04-01), Bosch et al.
patent: 5513803 (1996-05-01), Czekai et al.
patent: 5518187 (1996-05-01), Bruno et al.
patent: 5518738 (1996-05-01), Eickhoff et al.
patent: 5534270 (1996-07-01), De Castro
patent: 5552160 (1996-09-01), Livérside et al.
patent: 5560932 (1996-10-01), Bagchi et al.
patent: 5565188 (1996-10-01), Wong et al.
patent: 5569448 (1996-10-01), Wong et al.
patent: 5571536 (1996-11-01), Eickhoff et al.
patent: 5580579 (1996-12-01), Ruddy et al.
patent: 5587143 (1996-12-01), Wong
patent: 5591456 (1997-01-01), Franson et al.
patent: 5609998 (1997-03-01), Texter et al.
patent: 5611344 (1997-03-01), Bernstein et al.
patent: 5622938 (1997-04-01), Wong
patent: 5643605 (1997-07-01), Cleland et al.
patent: 5657931 (1997-08-01), Nair et al.
patent: 5662279 (1997-09-01), Czekai et al.
patent: 5662883 (1997-09-01), Bagchi et al.
patent: 5665331 (1997-09-01), Bagchi et al.
patent: 5676968 (1997-10-01), Lipp et al.
patent: 5691370 (1997-11-01), Cupps et al.
patent: 5716642 (1998-02-01), Bagchi et al.
patent: 5718919 (1998-02-01), Ruddy et al.
patent: 5747001 (1998-05-01), Wiedmann et al.
patent: 5759520 (1998-06-01), Sachetto
patent: 5762961 (1998-06-01), Roser et al.
patent: 5763445 (1998-06-01), Kruse et al.
patent: 5795978 (1998-08-01), Ansmann et al.
patent: 5919434 (1999-07-01), Dugstad et al.
patent: 5976574 (1999-11-01), Gordon
patent: 5985285 (1999-11-01), Titball et al.
patent: 6001336 (1999-12-01), Gordon
patent: 6565885 (2003-05-01), Tarara et al.
patent: 6800297 (2004-10-01), Altreuter et al.
patent: 6946117 (2005-09-01), Schutt et al.
patent: 2001/0018072 (2001-08-01), Unger
patent: 2002/0009493 (2002-01-01), Schwendeman et al.
patent: 2003/0035845 (2003-02-01), Zale et al.
patent: 2 136 704 (1995-05-01), None
patent: 37 13 326 (1987-10-01), None
patent: 0 655 237 (1995-05-01), None
patent: 1 265 615 (1972-03-01), None
patent: WO 98/31346 (1998-07-01), None
patent: WO 98/51282 (1998-11-01), None
patent: WO 99/56731 (1999-11-01), None
patent: WO 00/61147 (2000-10-01), None
Adeyeye & Price, “Chemical, dissolution stability and microscopic evaluation of suspensions of ibuprofen and sustained release ibuprofen-wax microspheres ,”J. Microencapsul. 14(3):357-77 (1997).
Ahn, et al., “Enhancement of bioavailability of ketoprofen using dry elixir as a novel dosage form,”Drug Dev. Ind. Pharm. 24(7):697-701 (1998).
Akade, et al., “Influence of polyethylene glycol 6000 and mannitol on the in-vitro dissolution properties of nitrofurantoin by the dispersion technique,”Pharmazie. 41(12):849-51 (1986).
Akbarieh & Tawashi, “Morphic features of solid particles after micronization in the fluid energy mill,”Int. J. Pharm. 35:81-89 (1987).
Allen, et al., “Dissolution rates of corticosteroids utilizing sugar glass dispersions,”J. Pharm. Sci. 66(4):494-97 (1977).
Appel & Zentner, “Use of modified ethylcellulose lattices for microporous coating of osmotic tablets,”Pharm. Res. 8(5):600-04 (1991).
Arias, et al., “Dissolution properties and in vivo behaviour of triamterene in solid dispersions with polyethylene glycols,”Pharm. Acta. Helv. 71(4):229-35 (1996).
Arias, et al., “The application of solid dispersion technique with D-mannitol to the improvement in oral absorption of triamterene,”J. Drug Target. 2(1):45-51 (1994).
Arteaga, et al., “Dissolution velocity of different calcium preparations used in the clinical field,”Rev. Med. Chil. 124(11):1325-33 (1996).
Badiger, et al., “Porogens in the preparation of microporous hydrogels based on poly(ethylene oxides),”Biomaterials14:1059-63 (1993).
Bodmeier & Paeratakul, “Spherical agglomerates of water-insoluble drugs,”J. Pharm. Sci. 78(11):964-67 (1989).
Borgström, et al., “In vitro and in vivo evaluation of controlled-release and enteric-coated formulations of sodium salicylate,”Biopharm. Drug Dispos. 5(3):261-72 (1984).
Buckton, et al., “The effect of comminution technique on the surface energy of a powder,”Int. J. Pharm. 47:121-28 (1998).
Cardorniga, et al., “In vitro evaluation of the dissolution rate of crystalline suspensions destined to intramuscular administration,”Eur. J. Drug Metab. Pharmacokinet. Spec No. 3:379-84 (1991).
Chaumeil, “Micronization: a method of improving the bioavailability of poorly soluble drugs,”Meth. Find Exp. Clin. Pharmacol. 20(3):211-15 (1998).
Chen & Hao, “Factors affecting zero-order release kinetics of porous gelatin capsules,”Drug Dev. Ind. Pharm. 24(6):557-62 (1998).
Chen & Hao, “In vitro performance of floating sustained-release capsule of verapamil,”Drug. Dev. Ind. Pharm. 24(11):1067-72 (1998).
Chiou & Riegelman, “Oral absorption of griseofulvin in dogs: increased absorption via solid dispersion in polyethylene glycol 6000,”J. Pharm. Sci. 59(7):937-42 (1970).
Chiou & Riegelman, “Pharmaceutical applications of solid dispersion systems,”J. Pharm. Sci. 60:1281-1302 (1971).
Chiou, et al., “Enhancement of dissolution rates of poorly water-soluble drugs by crystallization in aqueous surfactant solutions I: Sulfathiazole, Prednisone, and Chloramphenicol,”J. Pharm. Sci. 65:1702-04 (1976).
Christensen, et al., “Storage of polyvinylpyrrolidone (PVP) in tissues following long-term treatment with a PVP-containing vasopressin preparation,”Act. Med. Scand. 204:295-98 (1978).
Corrigan & Holohan, “Amorphous spray-dried hydroflumethiazide-polyvinylpyrrolidone systems: physiochemical properties,”J. Pharm. Pharmacol. 36(4):217-21 (1984).
De Almeida, et al., “Modeling dissolution of sparingly soluble multisized powders,”J. Pharm. Sci. 86:726-732 (1997).
Dordunoo, et al., “Physical stability of solid dispersions containing triamterene or temazepam in polyethylene glycols,”J. Pharm. Pharmacol. 49(4):390-96 (1997).
Dressman & Fleisher, “Mixing-tank model for predicting dissolution rate control or oral absorption,”J. Pharm. Sci. 75(2)

Affiliated with

Also associated with

Rating

Porous drug matrices and methods of manufacture thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Porous drug matrices and methods of manufacture thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Porous drug matrices and methods of manufacture thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2624268